Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma<sup>△</sup>

Nie Ke-ke; Geng Chuan-xin; Zhang Ling; Liu Shi-chao; Zhang Zhong-fa; Wang Rong; Zou Xiao; Ji You-xin

Your Location：

Home >

Browse articles >

Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma^△

中国医学科学杂志（英文版） 2016年31卷第4期页码：221-227

Orginal Article | Updated：2024-04-10

- Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma^△
- Affiliations：
  
  1. 1Department of Oncology, Qingdao Cancer Hospital, Qingdao, Shandong 266042, China
  2. 2ndDepartment of Oncology, Qingdao Central Hospital, 2nd Affiliated Hospital of Qingdao University, Qingdao,Shandong 266042, China
- Author bio：
  
  *Corresponding author Tel: 86-532-68665078, Fax: 86-532-84852500, E-mail: 123456789ji@gmail.com,niekekeqd@163.com
- Funds：
  
  △Supported by Medical Technology Research Center for Health Development Grant [W2012FZ007(YJ)].
- DOI：
  中图分类号：
- 网络出版日期：2016-08-20，
  
  纸质出版日期：2016-08
- Accepted：
Scan QR Code
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma^△[J]. 中国医学科学杂志（英文版）, 2016,31(4):221-227.

Nie Ke-ke, Geng Chuan-xin, Zhang Ling, et al. Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma^△[J]. Chinese medical sciences journal, 2016, 31(4): 221-227.
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma^△[J]. 中国医学科学杂志（英文版）, 2016,31(4):221-227. DOI：

Nie Ke-ke, Geng Chuan-xin, Zhang Ling, et al. Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma^△[J]. Chinese medical sciences journal, 2016, 31(4): 221-227. DOI：

摘要

Abstract

Objective

To investigate the clinical effects and safety of bevacizumab combined with S-1 as the second-line treatment of recurrent and/or metastatic esophageal cancer after chemoradiation.

Methods

Patients with recurrent or metastatic esophageal cancer after chemoradiation were treated with bevacizumab and S-1. Bevacizumab was used by intravenous infusion

7.5mg/kg body weight on day 1; S-1 was used by oral at 80mg/m

·d on day 1-14

21 days as a cycle of treatment and repeated until either pro- gressive disease or intolerable toxicity occurred. Chest CT were performed and RECIST 1.1 was used for response evaluation. Kaplan-Meier method was used for survival analysis. Side effects were recorded and analyzed.

Results

Totally 78 patients were enrolled in the study

including 67 squamous cell carcinoma and 11 adenocarcinoma histologically. The overall response (CR+PR) rate was 22.4% (17/76) and disease control (CR+PR+SD) rate was 61.8% (47/76) respectively. The median follow-up time was 20 months (range from 9 to 44 months). The median progression-free survival (PFS) was 4.9 months (95%

4.4-5.5) and the median overall survival (OS) was 8.1 months (95%

7.6-9.2). The median PFS and OS of patients with metastasis diseases were 6.2 months (95%

3.3 to 6.3) and 8.5 months (95%

5.8 to 11.2)

where PFS was longer than that of patients with local regional recurrence (median 5.0 months

95%

3.0 to 5.5

=0.017) and OS was longer than that of patients with regional disease and metastasis (median 8.0 months

95%

4.6 to 9.5

=0.010). The common adverse effects were mild to moderate neutropenia (84.2%)

grade I-II hand and foot syndrome (51.3%)

grade I-II nausea (48.7%)

mild epistaxis (30.1%) and mild vomiting (14.5%). Esophageal bleeding occurred in 7.9% of patients. One patient (1.3%) died from massive bleeding which was caused by esophageal perforation.

Conclusion

Bevacizumab combined with S-1 was effective and safe for esophageal cancer patients who had recurrent or metastatic diseases after chemoradiation.

关键词

Keywords

references

Jiménez F , Elias RE , Osella FJ , et al. Digestive tract cancer: after ten years in Santa Fe. Acta Gastroenterol Latinoam 2009 ; 39 : 242 - 9 .

Tian J , Chen JS. Time trends of incidence of digestive system cancers in changle of China during 1988-2002. World J Gastroenterol 2006 ; 12 : 4569 - 71 .

Tao Z , Cha Y , Sun Q. Cancer mortality in high background radiation area of Yangjiang, China, 1979-1995. Zhong Hua Yi Xue Za Zhi 1999 ; 79 : 487 - 92 .

Al Dulaimi D. Recent advances in esophageal diseases. Gastroenterol Hepatol Bed Bench 2014 ; 7 : 186 - 9 .

Lin D , Leichman L. The current status of neoadjuvant therapy for esophageal cancer. Semin Thorac Cardiovasc Surg 2014 ; 26 : 102 - 9 .

Shridhar R , Imani-Shikhabadi R , Davis B , et al. Curative treatment of esophageal cancer: an evidenced based review. J Gastrointest Cancer 2013 ; 44 : 375 - 84 .

Zondor SD , Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004 ; 38 : 1258 - 64 .

Chen HX. Expanding the clinical development of bevaci- zumab. Oncologist 2004 ; 9 Suppl 1 : 27 - 35 .

Ferrara N , Hillan KJ , Gerber HP , et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004 ; 3 : 391 - 400 .

Xia H , Shen J , Chen S , et al. Overexpression of VEGF-C correlates with a poor prognosis in esophageal cancer patients. Cancer Biomark 2016 ; 17 : 165 - 70 .

Möbius C , Freire J , Becker I , et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007 ; 31 : 1768 - 72 .

Sakata Y , Ohtsu A , Horikoshi N , et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998 ; 34 : 1715 - 20 .

Iwase H , Shimada M , Nakamura M , et al. A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer. Gan To Kagaku Ryoho 2002 ; 29 : 1575 - 82 .

Lee SR , Kim HO , Yoo CH. Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer. J Korean Surg Soc 2011 ; 81 : 163 - 8 .

Tanaka Y , Yoshida K , Tanahashi T , et al. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci 2016 ; 107 : 764 - 72 .

Oken MM , Creech RH , Tormey DC , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 : 5 : 649 - 56 .

Watanabe H , Okada M , Kaji Y , et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan To Kagaku Ryoho 2009 ; 36 : 2495 - 501 .

Trotti A , Colevas AD , Setser A , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003 ; 13 : 176 - 81 .

Kordes S , Cats A , Meijer SL , et al. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol 2014 ; 90 : 68 - 76 .

Idelevich E , Kashtan H , Klein Y , et al. Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie 2012 ; 35 : 427 - 31 .

Arii S , Mori A , Uchida S , et al. Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999 ; 12 : 25 - 30 .

Kleespies A , Guba M , Jauch KW , et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004 ; 87 : 95 - 104 .

Arjaans M , Oude Munnink TH , Oosting SF , et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013 ; 73 : 3347 - 55 .

Park I , Ryu MH , Choi YH , et al. A phase Ⅱ study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastro- esophageal junction adenocarcinoma. Cancer Chemother. Pharmacol 2013 ; 72 : 815 - 23 .

Ohashi M , Arai K , Iwasaki Y , et al. Two cases of advanced gastric cancer responding to TS-1: a novel oral formation of 5-fluorouracil. Gan To Kagaku Ryoho 2000 ; 27 : 1437 - 41 .

Sasaki T. Current topics of S-1 at the 74th Japanese Gastric Cancer Congress. Gastric Cancer 2003 ; 6 Suppl 19-12.

Koizumi W , Yamaguchi K , Hosaka H , et al. Randomised phase Ⅱ study of S-1/cisplatin plus TSU-68 vs S-1/ cisplatin in patients with advanced gastric cancer. Br J Cancer 2013 ; 109 : 2079 - 86 .

Hisashige A , Sasako M , Nakajima T. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer 2013 ; 13 : 443 .

Piessen G , Briez N , Triboulet JP , et al. Patients with locally advanced esophageal carcinoma nonresponder to radio- chemotherapy: who will benefit from surgery? Ann Surg Oncol 2007 ; 14 : 2036 - 44 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

暂无数据